Estetrol prevents western diet-induced obesity and atheroma independently of hepatic estrogen receptor (ER)α

Melissa Buscato (1) , Morgane Davezac (1) , Rana Zahreddine (1) , Marine Adlanmerini (1) , Raphaël Métivier (2) , Marianne Fillet (3) , Gael Cobraiville (3) , Cedric Moro (1) , Jean Michel J. M. Foidart (3) , Françoise Lenfant (1) , Pierre Gourdy (1) , Jean-Francois Arnal (4, 1) , Coralie Fontaine (1)

1 I2MC - Institut des Maladies Métaboliques et Cardiovasculaires
2 IGDR - Institut de Génétique et Développement de Rennes
3 Université de Liège
4 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse

Estetrol (E4), a natural estrogen synthesized by the human fetal liver, is currently evaluated in phase III clinical studies as a new menopause hormone therapy. Indeed, E4 significantly improves vasomotor and genito-urinary menopausal symptoms and prevents bone demineralization. Compared to other estrogens, E4 was found to have limited effects on coagulation factors in the liver of women allowing to expect less thrombotic events. To fully delineate its clinical potential, the aim of this study was to assess the effect of E4 on metabolic disorders. Here, we studied the pathophysiological consequences of a western diet (42% kcal fat, 0.2% cholesterol) in ovariectomized female mice under chronic E4 treatment. We showed that E4 reduces body weight gain and improves glucose tolerance in both C57Bl/6 and LDLR(-/-) mice. To evaluate the role of hepatic ERα in the preventive effect of E4 against obesity and associated disorders such as atherosclerosis and steatosis, mice harbouring a hepatocyte-specific ERα deletion (LERKO) were crossed with LDLR(-/-) mice. Our results demonstrated that, whereas liver ERα is dispensable for the E4 beneficial actions on obesity and atheroma, it is necessary to prevent steatosis in mice. Overall, these findings suggest that E4 could prevent metabolic, hepatic and vascular disorders occurring at menopause, extending the potential medical interest of this natural estrogen as a new hormonal treatment.

Mots clés: atherosclerosis; estrogen receptor; fatty liver; menopause; metabolic syndrome

Domaines: Sciences du Vivant [q-bio]; Endocrinologie et métabolisme

Melissa Buscato, Morgane Davezac, Rana Zahreddine, Marine Adlanmerini, Raphaël Métivier, et al.. Estetrol prevents western diet-induced obesity and atheroma independently of hepatic estrogen receptor (ER)α. AJP - Endocrinology and Metabolism, 2021, 320 (1), pp.E19-E29. ⟨10.1152/ajpendo.00211.2020⟩. ⟨hal-03006849⟩